[1]蒙建源,朱刚健.应用细胞免疫治疗肝细胞癌的研究[J].医学信息,2023,36(05):177-180.[doi:10.3969/j.issn.1006-1959.2023.05.037]
　MENG Jian-yuan,ZHU Gang-jian.Study on Cellular Immunotherapy for Hepatocellular Carcinoma[J].Journal of Medical Information,2023,36(05):177-180.[doi:10.3969/j.issn.1006-1959.2023.05.037]
点击复制

应用细胞免疫治疗肝细胞癌的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年05期
页码:
177-180
栏目:
综述
出版日期:
2023-03-01

文章信息/Info

Title:
Study on Cellular Immunotherapy for Hepatocellular Carcinoma
文章编号:
1006-1959（2023）05-0177-04
作者:
蒙建源; 朱刚健
（梧州市工人医院普外科一区，广西 梧州 543000）
Author(s):
MENG Jian-yuan; ZHU Gang-jian
(Zone 1 of General Surgery Department,Wuzhou Gongren Hospital,Wuzhou 543000,Guangxi,China)
关键词:
肝细胞癌; 肿瘤疫苗; 免疫检查点抑制剂; 过继性细胞免疫治疗; 细胞因子
Keywords:
Hepatocellular carcinoma; Tumor vaccines; Immune checkpoint inhibitors; Adoptive cellular immunotherapy; Cytokines
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2023.05.037
文献标志码:
A
摘要:
肝细胞癌为我国常见恶性肿瘤，其发病机制多变、异质性高、预后差，具有较高致死风险，除去常规治疗外，细胞免疫治疗已成为该病的重要研究方向。近年来，多项免疫疗法在HCC治疗中展现了良好的应用前景，包括肿瘤疫苗、免疫检查点抑制剂、过继性细胞免疫治疗、细胞因子、溶瘤病毒与溶瘤细菌等，其作用机制各异，为HCC的临床治疗提供了更多可能。现本文就当前HCC细胞免疫治疗的研究进展进行综述。
Abstract:
Hepatocellular carcinoma (HCC) is a common malignant tumor in China. Its pathogenesis is variable, with high heterogeneity, poor prognosis and high risk of death. In addition to conventional treatment, cell immunotherapy has become an important research direction of the disease. In recent years, a number of immune therapies have shown good application prospects in the treatment of HCC, including tumor vaccines, immune checkpoint inhibitors, adoptive cellular immunotherapy, cytokines, oncolytic viruses and oncolytic bacteria, etc., with different mechanisms of action, providing more possibilities for the clinical treatment of HCC. This article reviews the current research progress of HCC cell immunotherapy.

参考文献/References:

[1]张杰,段伯焕,朱功兵.肝细胞癌患者外科手术根治术后生存分析[J].实用肝脏病杂志,2017,20(1):93-96.[2]季学闻,马利兵,孙国洋,等.腹腔镜肝切除术对左外叶肝细胞癌患者免疫功能的影响及其远期疗效[J].现代生物医学进展,2017(20):119-122,161.[3]Ruf B,Heinrich B,Greten TF.Immunobiology and immunotherapy of HCC:spotlight on innate and innate-like immune cells[J].Chinese Journal of Immunology,2021,18(1):112-127.[4]Yutani S,Shirahama T,Muroya D,et al.Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies[J].Cancer Science,2017,108(9):1732-1738.[5]Nakagawa H,Mizukoshi E,Kobayashi E,et al.Association Between High-Avidity T-Cell Receptors, Induced by α-FetoproteinDerived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma[J].Gastroenterology,2017,152(6):1395-1406.[6]王艳梅,赵博慧,陈坤,等.诱导特异性CD8+T细胞产生的肝细胞癌相关新抗原分析[J].中华肿瘤杂志,2019,41(6):429-434.[7]胥冰,王巧侠,王小平,等.热休克蛋白70-甲胎蛋白抗原表位肽疫苗抗小鼠H22肝癌细胞免疫机制的研究[J].生物学杂志,2017,34(2):46-49.[8]Yutani S,Shirahama T,Muroya D,et al.Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies[J].Cancer Science,2017,108(9):1732-1738.[9]杨朵,周心娜,王硕,等.树突状细胞疫苗特异肿瘤多肽联合树突状细胞体外刺激淋巴细胞功能评估[J].北京大学学报:医学版,2021,53(6):1094-1098.[10]钭方芳,简艳,郭善娴,等.特异性表达Her-2抗原树突状细胞疫苗治疗非小细胞性肺癌体外抗瘤效应的研究[J].实用癌症杂志,2019,34(12):1915-1920.[11]隋洪涛,张彩华,宋文军,等.DC细胞疫苗干预肝癌Treg细胞及与IDO、IFN-γ等细胞因子相关性[J].贵州医药,2018,42(10):1173-1176.[12]Lee JH,Tak WY,Lee Y,et al.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phaseⅡ study[J].OncoImmunology,2017,6(7):e1328335.[13]Cao J,Kong FH,Liu X,et al.Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis[J].World J Gastroenterol,2019,25(27):3649-3663.[14]陈新,吴慧颖,邢晓娜.DNA疫苗对APP/PS1转基因鼠免疫反应类型及脑内炎症反应的影响[J].中国实验诊断学,2019,23(1):124-127.[15]林杰,王卫东,刘清波,等.GPC3 DNA疫苗对小鼠肝细胞癌特异杀伤机制探讨[J].中华肿瘤防治杂志,2019,26(4):221-225,238.[16]胡亚秋,汪妮,冉锡萍,等.评估免疫检查点抑制剂为基础的联合治疗在原发性肝癌患者中肝损伤发生情况的真实世界研究[J].中华肝脏病杂志,2022,30(1):57-62.[17]Goltz D,Gevensleben H,Vogt TJ,et al.CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients[J].JCI Insight,2018,3(13):e96793.[18]Yang J,Liu J,Chen Y,et al.Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study[J].Medicine,2019,98(29):e16266[19]Pinato DJ,Cortellini A,Sukumaran A,et al.PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma[J].BMC Cancer,2021,21(1):301.[20]Chen A,Greten T,Duffy A,et al.Imaging response of distant un-ablated hepatocellular carcinoma following limited hepatic thermal ablation combined with tremelimumab, a monoclonal antibody against CTLA4[J].Journal of Vascular & Interventional Radiology,2017,28(2):S60-S61.[21]Zhu AX,Finn RS,Julien E,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J].Lancet Oncol,2018,19(7):940-952.[22]El-Khoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.[23]Yau T,Park JW,Finn RS,et al.CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J].Annals of Oncology,2019,30(5):874-875.[24]Qin S,Ren Z,Meng Z,et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J].The Lancet Oncology,2020,21(4):571-580.[25]Zhang H,Song Y,Yang H,et al.Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis[J].Oncogene,2018,37(18):2456-2468.[26]汪琦,刘晓波,谭浩明,等.靶向人TIM3单抗制备及对肝癌细胞增殖的影响[J].中国免疫学杂志,2019,35(14):1735-1738.[27]刘海波,宁静,刘华胜,等.多细胞过继性免疫治疗治疗晚期恶性肿瘤的近期疗效及安全性分析[J].现代肿瘤医学,2019,27(7):1204-1207.[28]杨岩丽,廖丽,张婧,等.活化自体淋巴细胞过继性免疫治疗在原发性肝细胞癌中的疗效观察[J].中国肿瘤生物治疗杂志,2021,28(11):1098-1106.[29]Kalathil SG,Hutson A,Barbi J,et al.Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy[J].JCI Insight,2019,4(15):e130116.[30]辛梦,冯东峰,殷蓓蓓,等.乙型肝炎病毒相关性肝癌TACE术后干扰素治疗临床观察[J].中华肿瘤防治杂志,2018,25(9):652-658.[31]吴育民,杜端明,刘春霖,等.DNA-PK抑制剂联合溶瘤病毒增强对肝癌的抗肿瘤活性研究[J].中国免疫学杂志,2021,37(18):2231-2234,2239.[32]Fulgenzi CAM,Talbot T,Murray SM,et al.Immunotherapy in Hepatocellular Carcinoma[J].Current Treatment Options in Oncology,2021,22(10):87-92.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
　WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Journal of Medical Information,2018,31(05):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
　LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(05):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
　LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(05):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[4]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
　PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(05):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[5]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
　LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(05):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[6]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
　PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(05):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
[7]杨孟涛,汪 艇,杜 伟,等.miR-181b-5p靶向调控SPP1在肝细胞癌中过表达的临床意义及作用机制[J].医学信息,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
　YANG Meng-tao,WANG Ting,DU Wei,et al.Clinical Significance and Mechanism of miR-181b-5p Targeting to Regulate SPP1 Overexpression in Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(05):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
[8]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
　SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(05):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[9]唐 菀,张晓珣,柴 进.SLCO1B1在肝细胞癌中的表达及其对患者预后的影响[J].医学信息,2023,36(02):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
　TANG Wan,ZHANG Xiao-xun,CHAI Jin.Expression of SLCO1B1 in Hepatocellular Carcinoma and its Effect on Prognosis[J].Journal of Medical Information,2023,36(05):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
[10]张 政,卢鸿健,李明慧,等.基于生物信息学分析肝细胞癌中lncRNA-miRNA-mRNA的调控网络[J].医学信息,2023,36(06):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]
　ZHANG Zheng,LU Hong-jian,LI Ming-hui,et al.Analysis of lncRNA-miRNA-mRNA Regulatory Network in Hepatocellular Carcinoma Based on Bioinformatics[J].Journal of Medical Information,2023,36(05):1.[doi:10.3969/j.issn.1006-1959.2023.06.001]

更新日期/Last Update: 1900-01-01